Tirzepatide Boosts Long-Term Weight Loss After Lifestyle Intervention in Overweight Adults

Achieving significant weight loss through lifestyle changes is a crucial first step for individuals with obesity or who are overweight with comorbidities. However, the challenge of weight regain after initial success is widespread, often undermining long-term health benefits. This study addresses the critical need for strategies to sustain weight loss and prevent regain following an intensive lifestyle modification program.

Participants receiving Tirzepatide demonstrated significantly superior weight management compared to placebo. After 72 weeks of treatment, the Tirzepatide group achieved an additional mean weight loss of 15.7% from randomization (representing a total mean weight loss of 26.6% from baseline, assuming an initial 10.9% lifestyle-induced loss). In stark contrast, the placebo group experienced a mean weight regain of 2.5% from randomization. The most striking finding was that 85% of participants on Tirzepatide maintained at least 80% of their initial lifestyle-induced weight loss, compared to only 30% in the placebo group (p<0.001). Furthermore, 69% of Tirzepatide recipients achieved at least 20% total body weight loss from baseline, versus only 12% in the placebo group (p<0.001). Adverse events were consistent with previous Tirzepatide trials, primarily gastrointestinal and mild to moderate in severity.